Clinical trials: Recurrent Glioblastoma, IDH-Wildtype
Glioblastoma, IDH-wildtype, Glioblastoma
The RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma
Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site.
- Conditions
- Glioblastoma, IDH-wildtype, Glioblastoma, Glioblastoma Multiforme of Brain, Astrocytoma, Malignant
- Trial name
- RECMAP (NCT06273176)
- Testing
- Awake mapping under local anesthesia, Asleep mapping under general anesthesia, Resection under general anesthesia without mapping
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 225 people
- Sponsor
- Erasmus Medical Center
Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
TTFields Plus FET-PET-Guided Stereotactic Radiosurgery Versus TTFields Alone for Recurrent Glioblastoma (Tarrget 2.0)
This study evaluates whether the addition of FET-PET-guided stereotactic radiosurgery (SRS) to Tumor Treating Fields (TTFields) improves survival outcomes in patients with recurrent IDH-wildtype glioblastoma.
- Conditions
- Glioblastoma, Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastoma Multiforme, Adult
- Trial name
- NCT07668869
- Testing
- Tumor Treating Fields (TTFields), FET-PET-Guided Stereotactic Radiosurgery
- Where
- Poland
- Volunteers
- 92 people
- Sponsor
- Prof. Franciszek Lukaszczyk Memorial Oncology Center
Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma
Dosimetry, Safety, and Efficacy Study of [177Lu]Lu-XT771 in Patients With Recurrent Glioblastoma
The primary objective of this study is to evaluate the dosimetry, safety, and tolerability of the investigational radiopharmaceutical [177Lu]Lu-XT771 in patients with recurrent glioblastoma, an aggressive form of brain cancer.
- Conditions
- Recurrent Glioblastoma (WHO-Grade IV Glioma), Recurrent Glioblastoma, Glioblastoma (GBM), Recurrent Glioblastoma IDH Wildtype
- Trial name
- NCT07648823
- Testing
- [177Lu]Lu-XT771
- Where
- 2 sites in China
- Volunteers
- 5 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Glioblastom WHO Grade 4
Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma
This study evaluates the safety and specific antitumor immune responses of mRNA vaccines GV-108 and GV-907 in IDH-wildtype glioblastoma patients.
- Trial name
- NCT07520214
- Testing
- mRNA vaccine: GV-907、GV-108
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Beijing Neurosurgical Institute
Glioma, Malignant
Niraparib and Temozolomide in Patients Glioblastoma
The study evaluates safety, tolerability, pharmacokinetics at recommended phase II dose (RP2D) and preliminary antitumor activity of Niraparib + dd-TMZ "one week on, one week off" in patients affected by recurrent GBM IDH…
- Trial name
- ONC-2022-001 (NCT06258018)
- Testing
- Temodal, Niraparib
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Armando Santoro, MD
Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4
GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
This phase II trial compares the effect of GI-102 alone and in combination with pembrolizumab given before surgery in treating patients with IDH wildtype glioblastoma and IDH mutated grade 4 astrocytoma that has come back after a…
- Conditions
- Glioblastoma, IDH-Wildtype, Progressive Astrocytoma, IDH-Mutant, Grade 4, Progressive Glioblastoma, Progressive Gliosarcoma
- Trial name
- NCT07301268
- Testing
- Biospecimen Collection, Bispecific CD80-lgG4Fc-IL-2v Fusion Protein GI-102, Computed Tomography
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Mayo Clinic
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase I trial studies the side effects and best dose of Actimab-A when given together with cemiplimab (REGN2810) in treating patients with glioblastomas that have come back after a period of improvement (recurrent).
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma
- Trial name
- NCT07422363
- Testing
- Actinium Ac 225 Lintuzumab, Biospecimen Collection, Cemiplimab
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, Glioblastoma
Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma
This phase I/Ib trial tests the safety, side effects, and best dose of mycophenolate mofetil in combination with temozolomide and/or radiation therapy (standard of care) in treating patients with glioblastoma.
- Conditions
- Astrocytoma, Glioblastoma, Glioblastoma, IDH-Wildtype, MGMT-Unmethylated Glioblastoma
- Trial name
- NCT05236036
- Testing
- Mycophenolate Mofetil, Quality-of-Life Assessment, Radiation Therapy
- Where
- 3 sites in United States
- Volunteers
- 86 people
- Sponsor
- Northwestern University
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Recurrent Glioblastoma IDH Wildtype, Recurrent Glioblastoma
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
This study is testing a new way of treating brain tumours using tiny radioactive beads called SIR-Spheres® (90Y-labelled Resin Microspheres). These microspheres are placed into the blood vessels that feed the tumour.
- Trial name
- PRECISE (NCT07712770)
- Testing
- SIR-Spheres®
- Where
- Australia
- Volunteers
- 12 people
- Sponsor
- Olivia Newton-John Cancer Research Institute
Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4
Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy
This phase I trial tests the safety, side effects, and best dose of allogenic adipose-derived mesenchymal stem cells (AMSCs) in treating patients with glioblastoma or astrocytoma that has come back (recurrent) who are undergoing…
- Conditions
- Recurrent Glioblastoma, IDH-Wildtype, Recurrent Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, Grade IV
- Trial name
- NCT05789394
- Testing
- Allogeneic Adipose-derived Mesenchymal Stem Cells, Biospecimen Collection, Craniotomy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype
Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
This phase II trial tests the safety and side effects of efineptakin alfa and pembrolizumab in treating patients with glioblastoma that has come back (recurrent).
- Conditions
- High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
- Trial name
- NCT05465954
- Testing
- Biospecimen Collection, Efineptakin alfa, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Mayo Clinic
Glioblastoma, Glioblastoma, IDH-Wildtype
ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
This phase Ib trial tests the safety and side effects of ERAS-801 in treating patients with isocitrate dehydrogenase (IDH) wildtype, epidermal growth factor receptor (EGFR) amplified or mutated grade IV glioblastoma or…
- Conditions
- Glioblastoma, Glioblastoma, IDH-Wildtype, Gliosarcoma, Recurrent Glioblastoma, IDH-Wildtype
- Trial name
- NCT07089641
- Testing
- Biospecimen Collection, Echocardiography Test, EGFR Inhibitor ERAS-801
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Jonsson Comprehensive Cancer Center
IDH Family Wildtype, Recurrent Anaplastic Astrocytoma
Laser Interstitial Thermal Therapy and Lomustine in Treating Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma
This phase II trial studies how well laser interstitial thermal therapy and lomustine work in treating patients with glioblastoma or anaplastic astrocytoma that has come back.
- Conditions
- IDH Family Wildtype, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma
- Trial name
- NCT03022578
- Testing
- Laser Interstitial Thermal Therapy, Lomustine
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC)
Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)
The goal of this Phase I clinical trial is to evaluate how the imaging drug 203Pb- RMX-VH-PIB distributes in the body and how much radiation different organs receive in patients with glioblastoma multiforme (GBM) or pancreatic…
- Trial name
- RMX-VH (NCT07733674)
- Testing
- 203Pb-RMX-VHPIB injection, SPECT/CT Imaging
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Radiomedix, Inc.
Recurrent Glioblastoma IDH Wildtype
A Clinical Trial of P134 Cells in Recurrent Glioblastoma
This is an open-label, single-arm, dose-escalation and expansion Phase 1/2 clinical trial designed to evaluate the safety, tolerability and efficacy of P134 cells in patients with recurrent glioblastoma, to explore the maximum…
- Trial name
- NCT07318818
- Testing
- P134 cell injection
- Where
- China
- Volunteers
- 26 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Glioblastoma, Diffuse Glioma
Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild…
- Trial name
- NCT04910022
- Testing
- NMS-03305293, Temozolomide
- Where
- 18 sites in United States, Italy and 3 more
- Volunteers
- 150 people
- Sponsor
- Nerviano Medical Sciences
Recurrent Glioblastoma, IDH-Wildtype
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent).
- Trial name
- NCT06328036
- Testing
- Atezolizumab, Biospecimen Collection, Magnetic Resonance Imaging
- Sponsor
- National Cancer Institute (NCI)
Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden
This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden).
- Conditions
- Astrocytoma, IDH-Mutant, Grade 4, Diffuse Glioma, Glioblastoma, IDH-Wildtype, Secondary Glioblastoma
- Trial name
- NCT04145115
- Testing
- Ipilimumab, Magnetic Resonance Imaging, Nivolumab
- Where
- 414 sites in United States, Puerto Rico
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)